Plant Extracts as Possible Agents for Sequela of Cancer Therapies and Cachexia
1
College of Korean Medicine, Kyung Hee University, Hoegi-dong Dongdaemun-gu, Seoul 05253, Korea
2
Department of Pathology, College of Korean Medicine, Kyung Hee University, Hoegi-dong Dongdaemun-gu, Seoul 05253, Korea
3
Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Hoegi-dong Dongdaemun-gu, Seoul 05253, Korea
*
Author to whom correspondence should be addressed.
†
These authors equally contributed to this study.
Antioxidants 2020, 9(9), 836; https://doi.org/10.3390/antiox9090836
Received: 12 August 2020 / Revised: 4 September 2020 / Accepted: 4 September 2020 / Published: 7 September 2020
(This article belongs to the Special Issue Anti-inflammatory and Antioxidant Properties of Plant Extracts)
Cancer is a leading cause of the death worldwide. Since the National Cancer Act in 1971, various cancer treatments were developed including chemotherapy, surgery, radiation therapy and so forth. However, sequela of such cancer therapies and cachexia are problem to the patients. The primary mechanism of cancer sequela and cachexia is closely related to reactive oxygen species (ROS) and inflammation. As antioxidant properties of numerous plant extracts have been widely reported, plant-derived drugs may have efficacy on managing the sequela and cachexia. In this study, recent seventy-four studies regarding plant extracts showing ability to manage the sequela and cachexia were reviewed. Some plant-derived antioxidants inhibited cancer proliferation and inflammation after surgery and others prevented chemotherapy-induced normal cell apoptosis. Also, there are plant extracts that suppressed radiation-induced oxidative stress and cell damage by elevation of glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and regulation of B-cell lymphoma 2 (BcL-2) and Bcl-2-associated X protein (Bax). Cachexia was also alleviated by inhibition of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) by plant extracts. This review focuses on the potential of plant extracts as great therapeutic agents by controlling oxidative stress and inflammation.
View Full-Text
Keywords:
cancer sequela; cachexia; plant extracts; antioxidants; reactive oxygen species; oxidative stress; inflammation
▼
Show Figures
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Lee, J.; Jeong, M.I.; Kim, H.-R.; Park, H.; Moon, W.-K.; Kim, B. Plant Extracts as Possible Agents for Sequela of Cancer Therapies and Cachexia. Antioxidants 2020, 9, 836. https://doi.org/10.3390/antiox9090836
AMA Style
Lee J, Jeong MI, Kim H-R, Park H, Moon W-K, Kim B. Plant Extracts as Possible Agents for Sequela of Cancer Therapies and Cachexia. Antioxidants. 2020; 9(9):836. https://doi.org/10.3390/antiox9090836
Chicago/Turabian StyleLee, Jinjoo; Jeong, Myung I.; Kim, Hyo-Rim; Park, Hyejin; Moon, Won-Kyoung; Kim, Bonglee. 2020. "Plant Extracts as Possible Agents for Sequela of Cancer Therapies and Cachexia" Antioxidants 9, no. 9: 836. https://doi.org/10.3390/antiox9090836
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit